Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ZLAB - Zai Lab Limited - ADR


IEX Last Trade
19.98
0.430   2.152%

Share volume: 893,305
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$19.55
0.43
2.20%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
10%
Profitability 0%
Dept financing 3%
Liquidity 74%
Performance 6%
Company vs Stock growth
vs
Performance
5 Days
10.65%
1 Month
8.55%
3 Months
9.62%
6 Months
-4.13%
1 Year
-24.78%
2 Year
-54.01%
Key data
Stock price
$19.98
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$13.48 - $31.22
52 WEEK CHANGE
-$0.24
MARKET CAP 
1.986 B
YIELD 
N/A
SHARES OUTSTANDING 
99.609 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
BETA 
1.38
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$675,183
AVERAGE 30 VOLUME 
$625,139
Company detail
CEO:
Region: US
Website: http://www.zailaboratory.com/
Employees: 258
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

zai lab is a biopharmaceutical company dedicated to discovering, developing and commercializing innovative medicines. our vision is to address the largest unmet medical needs and transform patients’ lives around the world. we take a unique approach to combine both in-licensed products and internal r&d; to achieve a rich pipeline. we believe our drug candidates can be truly disease modifying and bring significant benefits to patients. the company was founded in 2013 by a group of industry veterans. the founders are known as pioneers in china’s fast advancing biotech industry with a proven track record for successful chinese cfda and us fda filings and approvals. our senior management team introduced fast regulatory approval pathways in china and developed a variety of partnership models with multinational pharmaceutical companies. we endeavor to conduct world class clinical development in china and beyond. zai lab has strong backing from a leading group of healthcare investors. our inve

Recent news